Lacosamide Vivanta (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes hyperexcitable neurons, reduces repetitive firing, and limits the spread of epileptic activity without markedly affecting normal rapid sodium channel function.

The specific dose and infusion rate of Lacosamide Vivanta are determined by the prescribing clinician based on the patient’s age, weight, renal function, and overall treatment plan. Healthcare professionals tailor the regimen to achieve optimal seizure control while minimizing adverse effects.

The pregnancy safety category for lacosamide is currently unknown. It should be used during pregnancy only if the potential therapeutic benefit justifies any potential risk to the fetus. Limited data are available regarding excretion in breast milk, so breastfeeding decisions should be made in consultation with a healthcare provider.

To request Lacosamide Vivanta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it generally has a favorable tolerability profile compared with some older sodium‑channel blockers that may cause more pronounced cardiac effects.

Lacosamide Vivanta must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to local regulations.

Lacosamide Vivanta is given as an intravenous infusion. The prescribing clinician determines the infusion rate and total daily dose, which are typically administered over a period of minutes to hours, depending on the patient’s clinical status and tolerance.

Serious risks include cardiac arrhythmias such as atrial fibrillation, severe skin reactions (e.g., Stevens‑Johnson syndrome), suicidal thoughts or behaviors, respiratory depression, and rare cases of anaphylaxis. Patients should be monitored closely for any signs of these events, especially during initiation and dose adjustments.

Lacosamide Vivanta is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is also advised for individuals with significant cardiac conduction abnormalities, uncontrolled arrhythmias, or severe renal impairment without appropriate medical supervision.